PLEK2 and lung cancer: Meanwhile, these findings suggested that its role as a biomarker was particularly significant in certain cancers, such as lung cancer and melanoma, where high PLEK2 levels correlate strongly with poorer clinical outcomes and reduced immunotherapy response.